Last reviewed · How we verify

TS-172 — Competitive Intelligence Brief

TS-172 (TS-172) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor antagonist. Area: Psychiatry.

phase 3 Serotonin receptor antagonist 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

TS-172 (TS-172) — Taisho Pharmaceutical Co., Ltd.. TS-172 is a small molecule that targets the serotonin receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TS-172 TARGET TS-172 Taisho Pharmaceutical Co., Ltd. phase 3 Serotonin receptor antagonist 5-HT2A receptor
Risperidone and Ramelteon Risperidone and Ramelteon All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic + melatonin receptor agonist combination Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Risperdal,reminyl Risperdal,reminyl Jinan Mental Hospital marketed Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl) Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
Quetiapine or Risperidone + Aripiprazole Quetiapine or Risperidone + Aripiprazole Otsuka Pharmaceutical Development & Commercialization, Inc. marketed Atypical antipsychotic Dopamine D2 receptor, serotonin 5-HT2A receptor
risperidone (Risperdal) risperidone (Risperdal) University of South Florida marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
sodium valproate with Clozapine sodium valproate with Clozapine Shanghai Mental Health Center marketed Antipsychotic + mood stabilizer combination Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase
Perospirone hydrochloride tablets Perospirone hydrochloride tablets Shanghai Mental Health Center marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor antagonist class)

  1. Addpharma Inc. · 2 drugs in this class
  2. Shire · 2 drugs in this class
  3. Gedeon Richter Plc. · 1 drug in this class
  4. Geropharm · 1 drug in this class
  5. H. Lundbeck A/S · 1 drug in this class
  6. Infan Industria Quimica Farmaceutica Nacional · 1 drug in this class
  7. Phytopharm Consulting Brazil · 1 drug in this class
  8. Taisho Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Aclaris Therapeutics, Inc. · 1 drug in this class
  10. Visirna Therapeutics HK Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TS-172 — Competitive Intelligence Brief. https://druglandscape.com/ci/ts-172. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: